An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201

Trial Profile

An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Ligelizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2017 Status changed from completed to discontinued.
    • 02 Aug 2016 Status changed from recruiting to completed.
    • 01 Jul 2016 The trial was completed in Germany (end date: 23 Mar 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top